AbbVie, in collaboration with Calico Life Sciences, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ABBV-CLS-628. This investigational therapy is a human monoclonal antibody being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder that causes cysts to grow on the kidneys. The Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. This designation for ABBV-CLS-628 acknowledges the therapy's potential to slow kidney function decline in patients with a high risk of rapidly progressing disease. Calico's CEO, Arthur D. Levinson, stated that the designation reflects the significant need within the ADPKD community for new treatments. With limited options currently available, the accelerated pathway could be crucial in bringing this potential therapy to patients more quickly. The safety and efficacy of ABBV-CLS-628 are still under evaluation in ongoing clinical studies. No specific market reaction to this announcement was available.